Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition
探讨全反式视黄酸和 PD-1 抑制治疗的人类受试者和 IDH 突变神经胶质瘤小鼠模型的抗肿瘤免疫机制
基本信息
- 批准号:10739154
- 负责人:
- 金额:$ 68.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-03 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAgeAntibodiesBiological MarkersBloodBrainBrain NeoplasmsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCellsCessation of lifeChemotherapy and/or radiationClinicalClinical TrialsCombined Modality TherapyDataDevelopmentDiffuseDisease remissionDoseEpigenetic ProcessEvaluationExcisionExclusionExhibitsFutureGene Expression ProfileGenetic TranscriptionGenotypeGliomaGoalsHematologic NeoplasmsHumanImmuneImmune checkpoint inhibitorImmune systemImmunocompetentImmunologic MarkersImmunologic MonitoringImmunologic SurveillanceImmunologicsImmunosuppressionImmunotherapeutic agentImmunotherapyInfiltrationInflammatoryInstitutional Review BoardsInterferon Type IIInterferonsIsocitrate DehydrogenaseKnowledgeLymphocyteLymphocyte FunctionLymphocytic InfiltrateMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMediatingMediatorModalityModelingMusMutationMyelogenousMyeloid-derived suppressor cellsNatural Killer CellsNeoadjuvant TherapyOperative Surgical ProceduresOutputPD-1 inhibitorsPathway interactionsPatientsPennsylvaniaPerformancePhase II Clinical TrialsPopulationPrediction of Response to TherapyRecurrenceRegimenRegulatory T-LymphocyteReportingResistanceRetinoidsSamplingSeriesSignal PathwaySignal TransductionSleeping BeautySolidSpecificitySpecimenT cell receptor repertoire sequencingT-Cell ActivationT-Cell ReceptorT-LymphocyteT-Lymphocyte and Natural Killer CellTechniquesTestingTherapeuticTherapeutically TargetableTissuesTretinoinTumor BiologyTumor ImmunityTumor TissueTumor-Infiltrating LymphocytesUniversitiesValidationXCL1 genecell typecheckpoint inhibitionclinical efficacycohortdesignepigenetic silencingexhaustionexperimental studygene networkgenetic signaturehuman subjectimmune checkpoint blockadeimmunogenicimmunogenicitymouse modelmutantneoplastic cellpre-clinicalpredicting responseprogrammed cell death protein 1responserestorationsmall moleculespecific biomarkerstranscriptome sequencingtreatment responsetumortumor eradicationyoung adult
项目摘要
Project Abstract
Diffuse gliomas are fatal brain tumors that respond poorly to current immunotherapies. Using
both mice models and human clinical trial data, we propose a series of experiments to identify
immune biomarkers and key immune cell types that predict tumor responsiveness to therapy.
These results will further our understanding of brain tumor biology and inform the future
development of new treatment modalities.
项目摘要
弥漫性神经胶质瘤是致命的脑肿瘤,对当前的免疫疗法反应不佳。使用
无论是小鼠模型还是人体临床试验数据,我们提出了一系列实验来确定
预测肿瘤对治疗反应的免疫生物标志物和关键免疫细胞类型。
这些结果将进一步加深我们对脑肿瘤生物学的理解并为未来提供信息
开发新的治疗方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nduka Mgbechinyere Amankulor其他文献
Nduka Mgbechinyere Amankulor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10458553 - 财政年份:2021
- 资助金额:
$ 68.31万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10220588 - 财政年份:2021
- 资助金额:
$ 68.31万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10620718 - 财政年份:2021
- 资助金额:
$ 68.31万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10415762 - 财政年份:2021
- 资助金额:
$ 68.31万 - 项目类别:
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
剖析年龄特异性佐剂体外和体内协同作用的机制
- 批准号:
9108575 - 财政年份:2016
- 资助金额:
$ 68.31万 - 项目类别:
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
CoVPN 3005:两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性 - LC 3
- 批准号:
10570739 - 财政年份:2006
- 资助金额:
$ 68.31万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10686595 - 财政年份:2006
- 资助金额:
$ 68.31万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - 两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成年人的功效、免疫原性和安全性
- 批准号:
10581414 - 财政年份:2006
- 资助金额:
$ 68.31万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10579557 - 财政年份:2006
- 资助金额:
$ 68.31万 - 项目类别: